Search
Arrowhead Pharmaceuticals Inc
ARWRAdd to Watchlist
62.400USD
+1.660+2.73%
Market hours 10/09, 11:58（ET）
8.79BMarket Cap
LossP/E TTM
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Arrowhead Pharmaceuticals Inc in the past month.
Buy
4 Strong Buy
10 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
107.128USD+66.89%
ARWR Analyst Recommendation Trends
In the current month, ARWR has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARWR average Analyst price target in the last month is 107.128.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
2
2
2
2
2
2
10
10
9
8
8
8
8
8
0
0
2
3
3
4
4
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
13
13
13
14
14
14
ARWR Analyst Rating for Peer Comparison
Updated: Oct 8, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, ARWR EPS is projected to reach -1.628 in FY2026Q4, following reported EPS of -1.355 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.25
-1.19
-1.32
-1.63
-1.37
Actual
0.22
-0.93
-1.36
--
--
Surprise
-11.13%
+21.50%
-2.65%
--
--
FAQs
What is Arrowhead Pharmaceuticals Inc's expected revenue for the next quarter?
Arrowhead Pharmaceuticals Inc's expected revenue is 53.23M.
What is Arrowhead Pharmaceuticals Inc's price target?
Analysts forecast that Arrowhead Pharmaceuticals Inc's price target is USD 107.13, with the highest forecast at USD 126.00 and the lowest forecast at USD 74.00.
How have Arrowhead Pharmaceuticals IncARWR's recent earnings per share performed?
The market expectation was USD -1.36, while Arrowhead Pharmaceuticals IncARWR's earnings per share (EPS) for the previous quarter was USD -0.93. EPS for the next quarter is expected at USD -1.63.
What is the analyst rating for Arrowhead Pharmaceuticals Inc?
Based on the ratings of Arrowhead Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.